Comparative Pharmacology
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus NOROXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus NOROXIN.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER vs NOROXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Noroxin (norfloxacin) is a fluoroquinolone antibacterial agent that inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination.
400 mg intravenously every 8-12 hours over 60 minutes.
400 mg orally twice daily for 3-14 days depending on indication.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-7 hours) in patients with normal renal function; extends to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 6-7 hours in patients with normal renal function. Prolonged to 21-28 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal excretion of unchanged drug accounts for approximately 50% of elimination, with 15% as metabolites; biliary/fecal excretion contributes about 20-35%.
Renal excretion accounts for approximately 30% of the dose as unchanged drug. Biliary/fecal elimination is a major route, with about 60-70% recovered in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic